Loading filters...
Publications per Year (916 total)
2
1995
1
·
1
·
1
·
3
·
4
2000
5
·
5
·
9
·
8
·
9
2005
17
·
11
·
13
·
9
·
19
2010
26
·
28
·
38
·
60
·
44
2015
42
·
52
·
55
·
61
·
54
2020
69
·
56
·
52
·
61
·
80
2025
21
·
Loaded
Click to load
50 / 916 papers loaded(scroll for more)
202620 papers
GeneralResectable (I-III)2026
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy for type 4 or large type 3 gastric cancer (OGSG 1402).
Tanaka R et al. Gastric Cancer. 2026
PD-L1 positiveAdvanced/Metastatic (IV)2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
Shitara K et al. Nat Med. 2026
GeneralAll Stages2026
Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701.
Endo S et al. Gastric Cancer. 2026
GeneralAll Stages2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study.
Dos Santos M et al. Eur J Cancer. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer.
Casak SJ et al. Clin Cancer Res. 2026
HER2-positiveAll Stages2026
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.
Sheng T et al. Gut. 2026
HER2-positiveAll Stages2026
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
Liu T et al. J Clin Oncol. 2026
GeneralResectable (I-III)2026
Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study.
Airoldi M et al. ESMO Open. 2026
HER2-positiveAll Stages2026
Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms.
Li W et al. Gastric Cancer. 2026
GeneralResectable (I-III)2026
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902).
Endo S et al. Gastric Cancer. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update.
Shah MA et al. J Clin Oncol. 2026
GeneralAll Stages2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.
Shitara K et al. ESMO Open. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.
Lee KW et al. Clin Cancer Res. 2026
HER2-positiveAll Stages2026
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.
Liu R et al. Ann Oncol. 2026
PD-L1 positiveAdvanced/Metastatic (IV)2026
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.
Janjigian YY et al. Ann Oncol. 2026
GeneralResectable (I-III)2026
A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma.
Kumagai K et al. J Gastroenterol. 2026
PD-L1 positiveAdvanced/Metastatic (IV)2026
Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapy.
Lee Y et al. Int J Cancer. 2026
GeneralAdvanced/Metastatic (IV)2026
Relative telomere length and senescence-associated inflammatory cytokines as blood-based prognostic markers in patients with advanced or resectable gastro-oesophageal adenocarcinoma.
Bilsland AE et al. Br J Cancer. 2026
GeneralResectable (I-III)2026
Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis.
Mateos L et al. Br J Cancer. 2026
GeneralResectable (I-III)2026
Survival Benefit of Adjuvant S-1 Chemotherapy in Patients Aged ≥ 80 Years with Gastric Cancer after Curative Resection: A Multicenter Cohort Study.
Sumiyoshi S et al. Ann Surg Oncol. 2026
202530 papers
GeneralResectable (I-III)2025
Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world.
Heckl SM et al. Gastric Cancer. 2025
GeneralResectable (I-III)2025
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
Raimondi A et al. J Clin Oncol. 2025
GeneralResectable (I-III)2025
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902).
Tanaka R et al. Gastric Cancer. 2025
GeneralAdvanced/Metastatic (IV)2025
A phase II study of trifluridine/tipiracil in combination with ramucirumab in advanced, refractory gastric, or gastroesophageal junction adenocarcinomas.
Kim DW et al. Oncologist. 2025
GeneralAdvanced/Metastatic (IV)2025
Efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as second-line therapy for advanced gastric cancer following failure of PD-1 inhibitor-containing treatment (TACTIC GC-01): A phase II single-arm study.
Ma X et al. Int J Cancer. 2025
GeneralAdvanced/Metastatic (IV)2025
Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.
Sun L et al. Oncologist. 2025
GeneralAdvanced/Metastatic (IV)2025
Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer.
Kim JW et al. Gastric Cancer. 2025
GeneralAll Stages2025
Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 versus oxaliplatin and S-1 for locally advanced gastric adenocarcinoma: A multicenter, real-world cohort study.
Jin P et al. Int J Cancer. 2025
GeneralResectable (I-III)2025
Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy.
Kraemer M et al. Int J Cancer. 2025
GeneralAdvanced/Metastatic (IV)2025
Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.
Liu Y et al. Int J Cancer. 2025
GeneralAll Stages2025
Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma.
Sugiyama K et al. Gastric Cancer. 2025
GeneralResectable (I-III)2025
Treatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy in patients with resectable gastric cancer: prospective randomized trial (PECORINO).
Dobrzhanskyi O et al. J Gastrointest Oncol. 2025
GeneralAdvanced/Metastatic (IV)2025
Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.
Janjigian YY et al. Nat Med. 2025
Claudin 18.2+Advanced/Metastatic (IV)2025
Retrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma.
Wallam S et al. J Gastrointest Oncol. 2025
GeneralAdvanced/Metastatic (IV)2025
Impact of maintenance therapy with fluoropyrimidines in advanced esophageal-gastric adenocarcinoma: a retrospective study in Mexican population.
Dip Borunda AK et al. J Gastrointest Oncol. 2025
PD-L1 positiveAdvanced/Metastatic (IV)2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
Kawakami H et al. J Clin Oncol. 2025
PD-L1 positiveAdvanced/Metastatic (IV)2025
An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.
Kadowaki S et al. Gastric Cancer. 2025
PD-L1 positiveAdvanced/Metastatic (IV)2025
Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis.
Nagaoka K et al. Gastric Cancer. 2025
PD-L1 positiveAdvanced/Metastatic (IV)2025
Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.
Lin D et al. Gastric Cancer. 2025
PD-L1 positiveAdvanced/Metastatic (IV)2025
A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901).
Kadota T et al. Gastric Cancer. 2025
PD-L1 positiveAll Stages2025
Lenvatinib suppress FGF19-FGFR4 signaling to enhance antitumor immune response in gastric cancer.
Maruyama Y et al. Gastric Cancer. 2025
PD-L1 positiveAdvanced/Metastatic (IV)2025
Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
Lee KW et al. Br J Cancer. 2025
PD-L1 positiveAdvanced/Metastatic (IV)2025
Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy.
Kim HD et al. Gastric Cancer. 2025
Claudin 18.2+Advanced/Metastatic (IV)2025
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.
Yamamoto K et al. ESMO Open. 2025
Claudin 18.2+Advanced/Metastatic (IV)2025
Zolbetuximab-related gastritis: a case report of the patient with prolonged gastrointestinal symptoms.
Sugiyama Y et al. Gastric Cancer. 2025
Claudin 18.2+Advanced/Metastatic (IV)2025
Expression of Claudin18.2 in metastatic lesions in peritoneum of gastric cancer.
Saito A et al. J Gastrointest Oncol. 2025
GeneralAdvanced/Metastatic (IV)2025
Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.
Samalin E et al. ESMO Open. 2025
GeneralAdvanced/Metastatic (IV)2025
Efficacy and safety of camrelizumab in combination with S-1 plus oxaliplatin sequenced by camrelizumab-based maintenance therapy as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort study.
Peng WR et al. J Gastrointest Oncol. 2025
GeneralAdvanced/Metastatic (IV)2025
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G).
Matsubara Y et al. Int J Cancer. 2025
GeneralAdvanced/Metastatic (IV)2025
Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study.
Narita Y et al. Oncologist. 2025